Compares blood-thinning medicines after a heart valve repair without a clot-thinner need
Compares two blood-thinning treatments in people with leaky mitral valves after catheter repair.
Plain-language title generated from the registry record
Registry title: STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who had a successful transcatheter edge-to-edge repair (TEER) for mitral regurgitation and do not need long-term blood thinners (oral anticoagulants).
- Sex
- All sexes can join.
- Disease stage
- Mitral regurgitation treated with a technically successful TEER procedure.
- Earlier treatment
- A successful TEER procedure is needed. People who need long-term oral anticoagulants cannot join.
Main reasons for not taking part
- Severe kidney problems (creatinine clearance < 15 mL/min or on dialysis)
- Ongoing bleeding after the TEER procedure, or vascular complications
- Need for long-term oral anticoagulant, or for dual antiplatelet therapy (for example after a recent PCI)
- Brain bleeding or stomach/bowel ulcer or bleeding in the last 12 months
- Pregnancy or breastfeeding
Read by machine on 12 November 2026.
Where in China
- Chinese Academy of Medical Sciences, Fuwai HospitalBeijing, ChinaContact: Xiangbin Pan, MD,PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Trial code
- NCT07007143
- Record updated
- 9 March 2026
- Original description
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients undergone TEER procedure. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients without an indication for OAC.Read full original descriptionShow less
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-edge Repair in Patients Without an Indication for Oral Anticoagulant: a Multicenter Randomized Controlled Trial
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients undergone TEER procedure. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients without an indication for OAC.
Inclusion: Successful TEER procedure, defined as technical success per MVARC criteria; Ability and willingness to comply with the trial protocol; Provision of written informed consent; Women of childbearing potential must use effective contraception from the time of consent until the final dose of antithrombotic therapy; Antithrombotic strategy approved by the investigator.
Exclusion: Participation in another investigational drug or device study within 30 days; Absolute indication for dual antiplatelet therapy; (eg, recent PCI); Recent ( < 12 month) intracranial or intracerebral hemorrhage; Recent ( < 12 month) gastrointestinal ulcers or hemorrhage; Hepatic disease with coagulopathy.(eg, Child-Pugh class B or C cirrhosis); Allergy, intolerance, or contraindication to research drugs; Severe renal impairment (creatinine clearance < 15 mL/min or requiring dialysis); Ongoing postoperative bleeding (defined as overt bleeding with a ≥3.0 g/dL drop in hemoglobin or requiring ≥3 units of blood transfusion), or vascular complications following the index TEER procedure; Platelet count < 50 × 10\^9 /L; Need for reoperation due to complications of the index TEER procedure; Indication for long-term OAC; Life expectancy < 12 months; Pregnancy or breastfeeding.